Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

CRISTEL Study: Monitoring of Pregnancies in Women After Solid Organ Transplantation (CRISTEL)

maanantai 11. toukokuuta 2026 päivittänyt: Hopital Foch
The objective of this research is to obtain standardized and independent data on the number of pregnancies occurring in France and their follow-up up to 1 year postpartum (or post-pregnancy termination). This study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will enable the dissemination of clear and up-to-date information to the medical community, thus contributing to better patient counseling and, more broadly, to couples. They will also serve to issue recommendations to optimize the planning and follow-up of pregnancies in women with solid organ transplants. Finally, this initiative aims to promote clinical research on pregnancies.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Interventio / Hoito

Yksityiskohtainen kuvaus

According to North American and Australian registries, pregnancy is both a joyful and high-risk event for women who have received a solid organ transplant. Typically, a transplanted woman has a probability comparable to that of the general population of giving birth to a live infant, but she is likely to deliver prematurely (median gestational age: 32 weeks), to have a growth-restricted baby (median birth weight around 2.3 kg), and often in a context of preeclampsia (in at least 30% of cases)(1).

Today, these are the data shared with patients planning a pregnancy, despite uncertainty as to their accuracy and applicability in France or even Europe.

Among the unknowns that remain despite these registry data, the following should be noted:

Uncertainty about the level of pregnancy planning in this specific context: What proportion of women of childbearing age have been informed of the possibility of becoming pregnant, of the associated risks, and of necessary precautions (e.g., stopping mycophenolate mofetil at least 6 weeks before conception);

Variability in the information provided from one center to another, due to the absence of a national, consensus-based document addressing fertility and contraception in the post-transplantation setting;

Monitoring frequency specific to the graft, especially regarding exposure to immunosuppressive drugs (and consequently actual exposure to calcineurin inhibitors, the cornerstone of anti-rejection therapy, whose residual blood concentration varies from the second trimester onward)(2);

The true risk of preeclampsia, at a time when diagnosis can be refined by measuring levels of placental-derived anti-angiogenic factors in maternal serum (sFlt-1/PlGF ratio)(3), and by uterine artery Doppler;

The incidence of de novo anti-HLA immunization (HLA antigens expressed by the fetus and inherited from the father), which can now be assessed using the Luminex technique(4);

Maternal morbidity: What is the impact of pregnancy on graft function? Conversely, how does renal function influence pregnancy outcomes, regardless of the transplanted organ?

Infant morbidity in the short and medium term.

To establish these data and to provide accurate information to patients, we aim to conduct a study among pregnant women who have undergone solid organ transplantation (kidney, heart, lung, liver, or pancreas). The objective of this research is to collect standardized and independent data on the number of pregnancies occurring in France and to monitor them up to one year postpartum (or after pregnancy termination).

The study will then aim to describe the clinical characteristics and maternal and perinatal outcomes of pregnancies in this specific population. These data will help disseminate clear and up-to-date information to the medical community, thus improving patient counseling and, more broadly, support for couples. They will also serve to develop recommendations to optimize the planning and management of pregnancies in women with solid organ transplants.

Finally, this initiative aims to promote clinical research on pregnancy in the context of transplantation, particularly through clinical trials and the development of biobanks.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

2000

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  • Female patient aged 18 years or older and of childbearing age
  • Has received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney)
  • Has a positive blood beta-hCG test result > 5 IU/L ("positive")
  • Has signed an informed consent form
  • Affiliated with a health insurance plan

Exclusion Criteria:

  • Patient deprived of liberty or under legal guardianship
  • Patient refuses to participate in the study

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Seulonta
  • Jako: Ei käytössä
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Muut: Adult female patients who have received a solid organ transplant
Adult female patients who have received a solid organ transplant, either isolated or combined (heart, liver, lung, pancreas, kidney), and who present with a positive beta-hCG blood test result (defined by a threshold of 5 IU/L) in one of the participating centers, or who are planning a pregnancy, will initially be identified.

Two optional (non-mandatory) biological samples may be collected as part of this study:

A 2 mL venous blood sample may be taken during a routine prenatal follow-up visit (around 30 weeks of gestation) in order to analyze the preeclampsia biomarker (sFlt-1/PlGF ratio), whenever preeclampsia is suspected.

A 5 mL sample from cord blood may be collected after delivery to analyze, in the newborn, the complete blood count, white blood cell differential, lymphocyte phenotyping (T CD3+, CD19+CD20+, and NK CD46+), and immunoglobulin levels (G, A, and M for humoral immunity, and E for allergy-related function).

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Aikaikkuna: Annually over the 10-year study period
The primary outcome is the annual incidence of conception in the population of women with solid organ transplants (i.e., included in the study).
Annually over the 10-year study period

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Rate of preeclampsia
Aikaikkuna: Through study completion, an average of 1 year
Rate of preeclampsia
Through study completion, an average of 1 year
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
Aikaikkuna: 3 months and 12 months postopartum
Trajectory of estimated glomerular filtration rate (eGFR, in mL/min/1.73 m²);
3 months and 12 months postopartum
Live birth rate among transplanted mothers from the onset of pregnancy.
Aikaikkuna: through study completion, an average of 1 year
Live birth rate among transplanted mothers from the onset of pregnancy.
through study completion, an average of 1 year
Trajectory of serum creatinine levels
Aikaikkuna: During pregnancy (up to 40 weeks if gestation)
Trajectory of serum creatinine levels
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Aikaikkuna: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal complications before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Aikaikkuna: Day of delivery: Perioperative/Periprocedural
Mode of delivery (spontaneous labor, induced labor, planned cesarean section, or emergency cesarean section); gestational age at delivery (in weeks of gestation); proportion of gestational hypertension and preeclampsia.
Day of delivery: Perioperative/Periprocedural
Birth weight of the newborn (in grams)
Aikaikkuna: day of delivery
Birth weight of the newborn (in grams)
day of delivery
Rate of spontaneous miscarriage
Aikaikkuna: Through study completion, an average of 1 year
Rate of spontaneous miscarriage
Through study completion, an average of 1 year
Rate of cesarean section
Aikaikkuna: Through study completion, an average of 1 year
Rate of cesarean section
Through study completion, an average of 1 year
Rate of prematurity
Aikaikkuna: Through study completion, an average of 1 year
Rate of prematurity
Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Aikaikkuna: Through study completion, an average of 1 year
Rate of intrauterine growth restriction
Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Aikaikkuna: Through study completion, an average of 1 year
the duration of hospital stay for both the mother and the newborn
Through study completion, an average of 1 year
incidence of biopsy-proven acute rejection up to 12 months postpartum;
Aikaikkuna: up to 12 months postpartum;
incidence of biopsy-proven acute rejection up to 12 months postpartum;
up to 12 months postpartum;
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
Aikaikkuna: 3 months and 12 months postoartum
incidence of de novo anti-HLA sensitization at 3 and 12 months postpartum.
3 months and 12 months postoartum
Trajectory of proteinuria (protein-to-creatinine ratio)
Aikaikkuna: During pregnancy (up to 40 weeks if gestation)
Trajectory of proteinuria (protein-to-creatinine ratio)
During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
Aikaikkuna: During pregnancy (up to 40 weeks if gestation)
Trajectory of tacrolimus blood levels, and anti-angiogenic factors during pregnancy,
During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
Aikaikkuna: During pregnancy (up to 40 weeks if gestation)
Trajectory of anti-angiogenic factors during pregnancy
During pregnancy (up to 40 weeks if gestation)
Rate of maternal complications and hospitalizations before delivery and in the postpartum period (infectious episodes, rejection episodes, therapeutic pregnancy termination, postpartum hemorrhage)
Aikaikkuna: During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Rate of maternal hospitalizations before delivery and in the postpartum period
During pregnancy (up to 40 weeks of gestation) and during post partum from delivery up to about 1 year after birth
Apgar score
Aikaikkuna: day of delivery
Apgar score
day of delivery
Proportion of growth-restricted
Aikaikkuna: day of delivery and up 3 month postpartum
Proportion of growth-restricted
day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
Aikaikkuna: day of delivery and up 3 month postpartum
Incidence of neonatal complications before the third month of life
day of delivery and up 3 month postpartum

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Päätutkija: Alexandre Pr Hertig, MED, Foch Hospital

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. syyskuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 1. syyskuuta 2036

Opintojen valmistuminen (Arvioitu)

Maanantai 1. syyskuuta 2036

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 22. syyskuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 11. toukokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 18. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 18. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 11. toukokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa